Optimization and validation of a high performance liquid chromatography method for rapid determination of sinafloxacin, a novel fluoroquinolone in rat plasma using a fused-core C(18)-silica column.
ABSTRACT A novel, simple and rapid high performance liquid chromatographic method has been developed and validated for the determination of sinafloxacin, a new fluoroquinolone, in rat plasma using 96-well protein precipitation, fused-core C(18)-silica column (4.6mmx50mm, 2.7microm) packed with a new solid support, which is made of 2.7microm particles that consist of a 1.7microm solid core covered with a 0.5microm thick shell of porous silica.The chromatographic separation was achieved with a mobile phase of 20:80 (v/v) of acetonitrile and phosphate buffer (pH=3.0) at a flow rate of 1mlmin(-1). Fluorescence detection was employed with lambda(ex) 295nm and lambda(em) 505nm. Lomefloxacin was used as internal standard (IS). The total analysis time was as short as 3min. The method was sensitive with a limit of detection (LOD) of 2ngml(-1), with good linearity (R(2)=0.9996) over the linear range of 5-500ngml(-1). The intra-day and inter-day precision was less than 5.8% and accuracy ranged from 100.3% to 103.5% for quality control (QC) samples at three concentrations of 10, 50 and 400ngml(-1).The fused-core C(18)-silica column method offered high sample throughput, low injection volume and low consumption of organic solvents. The method was successfully employed in the pharmacokinetic study of sinafloxacin formulation product after tail vein injection to healthy rats.
- [show abstract] [hide abstract]
ABSTRACT: A reversed-phase (RP) high-performance liquid chromatographic (HPLC) method with fluorescence detection allowing the sensitive and specific quantification of BAY 12-8039, a new antimicrobially active 8-methoxyquinolone, in biological fluids is described. The method is compared to a microbiological assay (bioassay) based on B. subtilis test strain with a limit of quantification of approximately 60 microg/l. Following dilution and centrifugation, plasma, saliva or urine supernatant is directly injected onto the HPLC system. Concentrations down to a limit of quantification of 2.5 microg/l can be quantified in plasma, saliva and urine. Data on recovery, accuracy and precision of the method throughout the whole working range as well as results on stability of the analyte are presented. The concentration data are correlated with results from the bioassay. BAY 12-8039 is stable in plasma after repeated freeze-thaw cycles and following storage at -20 degrees C for at least 12 months. The results of HPLC measurements excellently agree with bioassay data indicating the relevance of the method as a tool in clinical development to answer pharmacokinetic questions related to antimicrobial activity. The method was applied to human plasma, saliva and urine from subjects after a single oral dose of 400 mg of BAY 12-8039.Journal of chromatography. B, Biomedical sciences and applications 12/1997; 702(1-2):163-74.
- [show abstract] [hide abstract]
ABSTRACT: The chromatographic performance of a new brand of shell particles is compared to that of a conventional brand of totally porous silica particles having a similar size. The new material (Halo, Advanced Materials Technology, Wilmington, DE) is made of 2.7 microm particles that consist in a 1.7 microm solid core covered with a 0.5 microm thick shell of porous silica. The other material consists of the porous particles of a conventional 3 microm commercial silica-B material. These two columns have the same dimensions, 150 mm x 4.6mm. The reduced plate heights of two low molecular weight compounds, naphthalene and anthracene, two peptides (lys-bradykinin and bradykinin), and four proteins, insulin, lysozyme, beta-lactoglobulin, and bovine serum albumin were measured in a wide flow rate range and analyzed on the basis of the Van Deemter equation and of modern models for its terms. The Halo column provides a smaller axial diffusion coefficient B and a smaller eddy dispersion term A than the other column, a result consistent with its lower internal porosity (in(p)=0.19 versus 0.42) and with the narrower size distribution of its particles (sigma=5% versus 13%). The two columns have similar C terms for the two low molecular weight compounds and for the two peptides. However, the C term of the proteins that are not excluded is markedly lower on the column packed with the Halo particles than on the other column. A recent theoretical analysis of the mass transfer kinetics in shell particles predicts a C term for moderately retained proteins (3<k'<5) that is about 35% lower for shell than for fully porous particles while the experimental data show a value nearly 45% lower, an excellent agreement considering that the internal tortuosity of the particles might be different, affecting the ratio of the effective diffusivities (D(eff)) of the proteins in the two materials. Surprisingly, the Kozeny-Carman constant of the Halo packed column is 50% larger than that of the other column, in spite of which the permeability of the Halo column is slightly larger, due to its larger external porosity.Journal of Chromatography 08/2007; 1157(1-2):289-303. · 4.61 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: A 96-well protein precipitation, liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and fully validated for the determination of fudosteine in human plasma. After protein precipitation of the plasma samples (50 microL) by the methanol (150 microL) containing the internal standard (IS), erdosteine, the 96-well plate was vortexed for 5 min and centrifuged for 15 min. The 100 microL supernatant and 100 microL mobile phase were added to another plate and mixed and then the mixture was directly injected into the LC-MS/MS system in the negative ionization mode. The separation was performed on a XB-CN column for 3.0 min per sample using an eluent of methanol-water (60:40, v/v) containing 0.005% formic acid. Multiple reaction monitoring (MRM) using the precursor-product ion transitions m/z 178-->91 and m/z 284-->91 was performed to quantify fudosteine and erdosteine, respectively. The method was sensitive with a lower limit of quantification (LLOQ) of 0.02 microg mL(-1), with good linearity (r>0.999) over the linear range of 0.02-10 microg mL(-1). The within- and between-run precision was less than 5.5% and accuracy ranged from 94.2 to 106.7% for quality control (QC) samples at three concentrations of 0.05, 1 and 8 microg mL(-1). The method was employed in the clinical pharmacokinetic study of fudosteine formulation product after oral administration to healthy volunteers.Journal of Chromatography B 06/2008; 867(1):153-9. · 2.49 Impact Factor